Benzonatate

CHEMBL1374379 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

603.7 g/mol

LogP

2.4

Phase

4

A non-narcotic cough suppressant that works by numbing the stretch receptors in the airways and lungs, reducing the urge to cough. It is used to relieve uncomfortable, nonproductive coughing. Unlike opioid cough medicines, it does not affect the brain's cough center.

Molecular Weight

603.7000 g/mol

LogP

2.40

TPSA

121.00 Å²

Lipinski RO5

Fail

Mechanism of Action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCNc1ccc(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)cc1

InChI

InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3

Molecular Formula

C30H53NO11

HBD / HBA

1 / 12

Rotatable Bonds

33

Heavy Atoms

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A non-narcotic cough suppressant that works by numbing the stretch receptors in the airways and lungs, reducing the urge to cough. It is used to relieve uncomfortable, nonproductive coughing. Unlike opioid cough medicines, it does not affect the brain's cough center.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Benzonatate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1374379. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 7699. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Benzonatate on PillFYI

Structure

Quick Data

Formula: C30H53NO11

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.